Onxeo Financial Statements From 2010 to 2025
| C4X Stock | EUR 0.05 0 2.88% |
Check Onxeo SA financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Onxeo SA's main balance sheet or income statement drivers, such as , as well as many indicators such as . Onxeo financial statements analysis is a perfect complement when working with Onxeo SA Valuation or Volatility modules.
Onxeo |
Onxeo SA Company Current Valuation Analysis
Onxeo SA's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Onxeo SA Current Valuation | 5.34 M |
Most of Onxeo SA's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Onxeo SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Onxeo SA has a Current Valuation of 5.34 M. This is 99.96% lower than that of the Healthcare sector and 99.88% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 99.97% higher than that of the company.
Onxeo SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Onxeo SA's current stock value. Our valuation model uses many indicators to compare Onxeo SA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Onxeo SA competition to find correlations between indicators driving Onxeo SA's intrinsic value. More Info.Onxeo SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Onxeo SA's earnings, one of the primary drivers of an investment's value.About Onxeo SA Financial Statements
Onxeo SA stakeholders use historical fundamental indicators, such as Onxeo SA's revenue or net income, to determine how well the company is positioned to perform in the future. Although Onxeo SA investors may analyze each financial statement separately, they are all interrelated. For example, changes in Onxeo SA's assets and liabilities are reflected in the revenues and expenses on Onxeo SA's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Onxeo SA. Please read more on our technical analysis and fundamental analysis pages.
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. Onxeo SA was incorporated in 1997 and is headquartered in Paris, France. ONXEO S operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 29 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Onxeo Stock
Onxeo SA financial ratios help investors to determine whether Onxeo Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Onxeo with respect to the benefits of owning Onxeo SA security.